• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@Medipol
  • Fakülteler
  • Tıp Fakültesi
  • Makale Koleksiyonu
  • View Item
  •   DSpace@Medipol
  • Fakülteler
  • Tıp Fakültesi
  • Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: A multicenter study

Thumbnail

View/Open

Tam Metin / Full Text (505.5Kb)

Access

info:eu-repo/semantics/embargoedAccess

Date

2021

Author

Akdeniz, Nadiye
Kaplan, Muhammet Ali
Uncu, Doğan
İnanç, Mevlüde
Kaya, Serap
Dane, Faysal
Küçüköner, Mehmet
Demirci, Ayşe
Bilici, Mehmet
Gök Durnalı, Ayşe
Koral, Lokman
Şendur, Mehmet Ali Nahit
Erol, Cihan
Türkmen, Esma
Ölmez, Ömer Fatih
Açıkgöz, Özgür
Laçin, Şahin
Şahinli, Hayriye
Urakçı, Zuhat
Işıkdoğan, Abdurrahman

Metadata

Show full item record

Citation

Akdeniz, N., Kaplan, M. A., Uncu, D., İnanç, M., Kaya, S., Dane, F. ... Işıkdoğan, A. (2021). The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: A multicenter study. International Journal of Colorectal Disease, 36(6), 1311-1319. https://dx.doi.org/10.1007/s00384-021-03888-9

Abstract

Purpose We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal cancer (CRC). Methods Five hundred and seventy patients with stage III colorectal carcinoma who received different FOLFOX regimens after curative resection were included. Patients were divided into three groups as FOLFOX-4, modified FOLFOX-6 (mFOLFOX-6), and mFOLFOX-4 for comparison of toxicity and disease-free survival (DFS) and overall survival (OS) times. Results Three-year DFS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 65%, 72%, and 72%, respectively. Five-year OS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 69%, 75%, and 67%, respectively. There was no statistically significant difference between the three treatment groups in terms of DFS and OS (p = 0.079, and p = 0.147, respectively). Among grade 1-2 adverse events (AE), thrombocytopenia, neuropathy, and stomatitis were more common in the mFOLFOX-6-treated group. The frequency of grade 1-2 nausea and vomiting were similar in mFOLFOX-6 (36.3% and 24%, respectively) and mFOLFOX-4 (32.4% and 24.7%, respectively) groups but were higher than that in the FOLFOX-4 (19.5% and 11.3%, respectively) group. Among the most common grade 3-4 AE, neutropenia (53.4%, 9%, and 13.5%, respectively) and diarrhea (10.5%, 2.2%, and 2.4, respectively) were more common in FOLFOX-4. The rate of anemia and febrile neutropenia was similar in treatment groups (p = 0.063, and p = 0.210, respectively). Conclusion In the adjuvant treatment of stage III CRC patients, three different 5-FU administration types in FOLFOX combination treatment can be used with similar efficiency and manageable toxicity.

WoS Q Kategorisi

Q2

xmlui.dri2xhtml.METS-1.0.item-scopusquality

Q2

Source

International Journal of Colorectal Disease

Volume

36

Issue

6

URI

https://dx.doi.org/10.1007/s00384-021-03888-9
https://hdl.handle.net/20.500.12511/8488

Collections

  • Makale Koleksiyonu [3448]
  • PubMed İndeksli Yayınlar Koleksiyonu [3758]
  • Scopus İndeksli Yayınlar Koleksiyonu [5797]
  • WoS İndeksli Yayınlar Koleksiyonu [5977]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Guide | Contact |

DSpace@Medipol

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide || Library || İstanbul Medipol University || OAI-PMH ||

Kütüphane ve Dokümantasyon Daire Başkanlığı, İstabul, Turkey
If you find any errors in content, please contact: [email protected]

Creative Commons License
DSpace@Medipol by İstanbul Medipol University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Medipol:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.